Bambusa Therapeutics, Inc. (BBTX) stock analysis
BBTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$16.09−0.66 (-3.94%)
Close on Nov 13, 2026Market cap –P/E –Yield –
Analysis
Not enough annual history yet
Analysis needs at least two fiscal years of reported financials for Bambusa Therapeutics.
See a number that looks wrong?